We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Prostate Cancer Risk Test Based on Urine-Derived EV-RNA

By LabMedica International staff writers
Posted on 08 Jul 2019
Print article
Image: A micrograph showing a prostate cancer (conventional adenocarcinoma) with perineural invasion (Photo courtesy of Wikimedia Commons).
Image: A micrograph showing a prostate cancer (conventional adenocarcinoma) with perineural invasion (Photo courtesy of Wikimedia Commons).
A team of British researchers developed a prostate cancer risk classifier using urine-derived extracellular vesicle (EV)-RNA capable of providing diagnostic information on disease status prior to biopsy, and prognostic information for men on active surveillance.

Currently diagnostic tests for prostate cancer are not sufficiently specific to be able to differentiate those without prostate cancer, those with low risk disease that is unlikely to be of clinical significance, and those with disease that should be treated. To rectify this situation, investigators at the University of East Anglia's Norwich Medical School (Norwich, United Kingdom) developed a diagnostic classification system based on RNA profiles found in extracellular vesicles (EVs) in urine.

These are cell-derived vesicles that are present in many and perhaps all biological fluids, including blood, urine, and cultured medium of cell cultures. The vesicles, which contain RNA, proteins, lipids, and metabolites that are reflective of the cell type of origin, are either released from the cell when multivesicular bodies (MVBs) fuse with the plasma membrane, or they are released directly from the plasma membrane.

In the current study, the investigators determined post-digital rectal examination urine-derived EV-RNA expression profiles from samples provided by 535 centers.

By analyzing the cell-free expression of 167 genes in urine samples, the investigators identified a mathematical combination of 35 different genes that could be used to generate four prostate urine risk (PUR) signatures for predicting the probability of normal tissue (PUR-1), D'Amico low-risk (PUR-2), intermediate-risk (PUR-3), and high-risk (PUR-4) prostate cancer. This model was applied to a test cohort of 117 samples for diagnostic evaluation, and to an active surveillance sub-cohort of 87 samples for prognostic evaluation.

Results revealed that application of PUR provided a net benefit over current clinical practice, since each PUR signature was significantly associated with its corresponding clinical category. Furthermore, PUR-4 status predicted the presence of clinically significant intermediate- or high-risk disease.

Senior author Dr. Jeremy Clark, a senior research associate at Norwich Medical School, said, "This research shows that our urine test could be used to not only diagnose prostate cancer without the need for an invasive needle biopsy but to identify a patient's level of risk. This means that we could predict whether or not prostate cancer patients already on active surveillance would require treatment.

The really exciting thing is that the test predicted disease progression up to five years before it was detected by standard clinical methods. Furthermore, the test was able to identify men that were up to eight times less likely to need treatment within five years of diagnosis. If this test was to be used in the clinic, large numbers of men could avoid an unnecessary initial biopsy and the repeated, invasive follow-up of men with low-risk disease could be drastically reduced."

The Prostate Urine Risk study was published in the May 20, 2019, online edition of the journal BJU International.

Related Links:
University of East Anglia Norwich Medical School

Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
New
Thyroid ELISA Kit
AESKULISA a-TPO

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The FDA clearance for the QIAstat-Dx Respiratory Panel Mini test follows the recent approval of QIAstat-Dx Respiratory Panel Plus (Photo courtesy of QIAGEN)

Respiratory Panel to Help Clinicians Make Precise Treatment Decisions in Outpatient Settings

Respiratory tract infections are the primary reason for visits to emergency departments and subsequent hospitalizations. In the U.S., it is estimated that there are up to 41 million cases of influenza... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: The new technique allows properties of cancer cells and their surrounding tissue to be analyzed in detail at single-cell level (Photo courtesy of Universität Helsinki/Karolina Punovuori)

New Imaging Method Opens Door to Precision Diagnostics for Head and Neck Cancers

Head and neck cancers, while considered rare, represent a significant portion of cancer cases and have seen a notable increase over the past 30 years. These cancers encompass various malignant tumors that... Read more